Devyser Diagnostics AB (publ) (DVYSR)

Nasdaq Stockholm | Biotech | Genetic diagnostic test kits
Free
No email, no account, no signup.
Pulling latest news for Devyser Diagnostics AB (publ)…
Bull
Bear
Preliminary read — single AI model. The deep report cross-checks with four.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
Nasdaq Stockholm
Type
Biotech
Sector
Genetic diagnostic test kits
Market Cap
$169M
We're already tracking Devyser Diagnostics AB (publ) — here are the latest events we've registered

Recent News

  • On April 1, 2026, Devyser completed the acquisition of CyberGene AB, a Swedish molecular diagnostics company. In the Q1 2026 report released on April 27, the company reported its fourth consecutive quarter of positive operating results (EBIT).
Want to know how this news affects Devyser Diagnostics AB (publ)? Order the analysis.
Order analysis – $4.99

What you get

A complete express analysis — not just a signal. Delivered as a webpage in your account.

  • Signal: BUY / HOLD / SELL — with clear reasoning
  • Sentiment score 1–10 based on news, reports, and market data
  • Risk score 1–10 (dilution, jurisdiction, execution)
  • Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
  • Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
  • Upcoming catalysts with dates
  • Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Devyser Diagnostics AB (publ) will be delivered in the same format.

Sample analyses in the same sector

Click to see what a complete analysis looks like.

Swedish Orphan Biovitrum AB (publ)
SOBI
HOLD
Liquidia Corporation
LQDA
BUY
Cereno Scientific B
CRNO B
HOLD
Dyne Therapeutics, Inc.
DYN
NEUTRAL
Sprint Bioscience AB (publ)
SPRINT
NEUTRAL
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
Devyser Diagnostics AB (publ) (DVYSR)
Fresh analysis on demand
Order analysis – $4.99
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.